thrombophilia screening

PreclinicalBiologic

CCentral Hospital, Nancy, France

thrombophilia screening is one of 5 biologic programs targeting Thrombophilia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ThrombophiliaActive, not recruiting

ThrombophiliaPreclinical

Active, not recruiting

Competition

Competitive Landscape

5 competitors in Thrombophilia

#DrugCompanyPhaseTrials

Bayer Aspirin

Plavix

Dalteparin Sodium

1 4

Nadroparin Calcium

Italfarmaco

Phase 3

1 5

thrombophilia screening

CCentral Hospital, Nancy, France

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Thrombophilia1 trial

Thrombophilia Screening After Severe IUGR

Unknown status·—··NCT05551078·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for thrombophilia screening. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — thrombophilia screening compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for thrombophilia screening. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Central Hospital, Nancy, France company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: CCentral Hospital, Nancy, France

thrombophilia screening

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Thrombophilia1 trial

References

Drug Info

Quick Facts

Related News